Pfizer Dashes Hopes For A PCSK9 Pill
Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.
You may also be interested in...
Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.
Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.
The big pharma’s chief executive assured investors there is no expiration date on optionality, suggesting the company could always reconsider splitting up the business even if decides against such action this year.